Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
C3d regulates immune checkpoint blockade and enhances antitumor immunity
Jeffrey L. Platt, … , Michael C. Carroll, Marilia Cascalho
Jeffrey L. Platt, … , Michael C. Carroll, Marilia Cascalho
Published May 4, 2017
Citation Information: JCI Insight. 2017;2(9):e90201. https://doi.org/10.1172/jci.insight.90201.
View: Text | PDF
Research Article Immunology

C3d regulates immune checkpoint blockade and enhances antitumor immunity

  • Text
  • PDF
Abstract

Despite expression of immunogenic polypeptides, tumors escape immune surveillance by engaging T cell checkpoint regulators and expanding Tregs, among other mechanisms. What orchestrates these controls is unknown. We report that free C3d, a fragment of the third component of complement, inside tumor cells — or associated with irradiated tumor cells and unattached to antigen — recruits, accelerates, and amplifies antitumor T cell responses, allowing immunity to reverse or even to prevent tumor growth. C3d enhances antitumor immunity independently of B cells, NK cells, or antibodies, but it does so by increasing tumor infiltrating CD8+ lymphocytes, by depleting Tregs, and by suppressing expression of programmed cell death protein 1 (PD-1) by T cells. These properties of C3d appear specific for the tumor and dependent on complement receptor 2, and they incur no obvious systemic toxicity. The heretofore unrecognized properties of free C3d suggest that protein might determine the effectiveness of immune surveillance and that increasing availability of the protein might prove advantageous in the treatment or prevention of cancer and premalignant conditions.

Authors

Jeffrey L. Platt, Inês Silva, Samuel J. Balin, Adam R. Lefferts, Evan Farkash, Ted M. Ross, Michael C. Carroll, Marilia Cascalho

×

Figure 4

Impact of C3d on CD21 expression by Tregs, on apoptosis of Tregs, and on Treg frequencies following vaccination against melanoma.

Options: View larger image (or click on image) Download as PowerPoint
Impact of C3d on CD21 expression by Tregs, on apoptosis of Tregs, and on...
Graphs reflect analysis of lymphocytes obtained from tumor-draining lymph nodes of 4–5 mice/group 14 days after tumor transfer. Mice were vaccinated by injection of 1 × 107 killed melanoma cells 35 days prior to transfer of 2 × 105 live tumor cells. Vaccinated mice were challenged with C3d– tumor cells (expressing empty vector marker). (A) Frequency of apoptotic Treg (CD4+, Foxp3+, caspase 3+ and -6+/CD4+, Foxp3+ cells × 100) in nonvaccinated or vaccinated mice determined by flow cytometry. (B) Tumor size (measured as areas) in the mice corresponding to the lymphocyte analysis. (C) Frequency of CD21+ Tregs (CD4+, CD21+, Foxp3+/CD4+ × 100). (D) Plot compares the frequencies of CD21+ Tregs with the respective tumor sizes. Each dot represents one mouse. (E) Frequency of Tregs (CD4+, Foxp3+/CD4+ × 100) determined by flow cytometry. (F) Plot compares the frequencies of Tregs with the respective tumor sizes. Each dot represents one mouse. Boxes in graphs represent distribution of data between the 25th and the 75th percentiles. The mean is indicated by a horizontal line, and whiskers represent maximum and minimum values. Statistical analysis in A, B, C, and E was by the Kruskal Wallis test followed by Dunn’s multiple comparison test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts